PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21192914-5 2011 Phorbol ester (PMA) activates MGF synthesis in human myoblasts and myotubes only. Tetradecanoylphorbol Acetate 15-18 insulin like growth factor 1 Homo sapiens 30-33 21192914-7 2011 Stimulation of MGF expression in human cells by db-cAMP and PMA demonstrated different time dependences but showed additivity when the compounds were applied in a combination. Tetradecanoylphorbol Acetate 60-63 insulin like growth factor 1 Homo sapiens 15-18 11825899-10 2002 These observations suggest that the increase of C/EBP beta binding to the C/EBP site, which is in part mediated via activation of RSK, can primarily explain the TPA responsiveness of the IGF-I gene promoter. Tetradecanoylphorbol Acetate 161-164 insulin like growth factor 1 Homo sapiens 187-192 19420001-4 2009 The growth factors IGF-I and acidic FGF induced the highest increase in PTPalpha phosphorylation at tyrosine 789, followed by PMA and lysophosphatidic acid, while EGF had little effect. Tetradecanoylphorbol Acetate 126-129 insulin like growth factor 1 Homo sapiens 19-24 17617058-8 2007 In cells, the IGF-1-stimulated phosphorylations, and certain EGF-stimulated phosphorylations, were inhibited by PI3K (phosphoinositide 3-kinase) inhibitors, whereas the RSK inhibitor BI-D1870 inhibited the PMA-induced phosphorylations. Tetradecanoylphorbol Acetate 206-209 insulin like growth factor 1 Homo sapiens 14-19 11825899-3 2002 Treatment with 12-O-tetradecanoylphorbol 13-acetate (TPA) caused an increase in the activity of the human IGF-I gene major promoter in HepG2 cells. Tetradecanoylphorbol Acetate 15-51 insulin like growth factor 1 Homo sapiens 106-111 9869604-8 1999 Long-term exposure of cells to phorbol myristate acetate caused the depletion of PKC-delta and -gamma and prevented also IGF-I-induced cell motility. Tetradecanoylphorbol Acetate 31-56 insulin like growth factor 1 Homo sapiens 121-126 11825899-3 2002 Treatment with 12-O-tetradecanoylphorbol 13-acetate (TPA) caused an increase in the activity of the human IGF-I gene major promoter in HepG2 cells. Tetradecanoylphorbol Acetate 53-56 insulin like growth factor 1 Homo sapiens 106-111 11884618-5 2002 In several types of mammalian cells, RACK1 interacted with IGF-IR, protein kinase C, and beta1 integrin in response to IGF-I and phorbol 12-myristate 13-acetate stimulation. Tetradecanoylphorbol Acetate 129-160 insulin like growth factor 1 Homo sapiens 59-64 10625638-9 2000 Calphostin C, a selective inhibitor of PKC, decreased the PMA-, PTH-, and IGF-I-induced luciferase activity in a dose-dependent manner; a PKA inhibitor, H-89, also blocked the induction by PTH and IGF-I but not by PMA. Tetradecanoylphorbol Acetate 58-61 insulin like growth factor 1 Homo sapiens 197-202 10625638-9 2000 Calphostin C, a selective inhibitor of PKC, decreased the PMA-, PTH-, and IGF-I-induced luciferase activity in a dose-dependent manner; a PKA inhibitor, H-89, also blocked the induction by PTH and IGF-I but not by PMA. Tetradecanoylphorbol Acetate 214-217 insulin like growth factor 1 Homo sapiens 74-79 8703583-3 1996 Scatchard analysis of 125I-labeled IGF-I to FLG 29.1 cells revealed the presence of a single high affinity binding site in both untreated and TPA-treated cells with a similar Kd value (0.3 +/- 0.2 nmol/L and 0.4 +/- 0.1 nmol/L, respectively). Tetradecanoylphorbol Acetate 142-145 insulin like growth factor 1 Homo sapiens 35-40 9618150-6 1998 Cotransfection with dominant-negative p85 or with dominant-negative Ras also produced down-regulation of the insulin or IGF-I-induced 12-O-tetradecanoylphorbol-13-acetate response element (TRE)-CAT (five AP-1, activating protein-1, binding sites arranged in tandem) transactivation. Tetradecanoylphorbol Acetate 134-170 insulin like growth factor 1 Homo sapiens 120-125 9025718-2 1996 In this study, human neuroblastoma SH-SY5Y cells have been treated with IGF-I and its potent analogue des(1-3)IGF-I alone or following preincubation with a differentiating agent such as 12-o-tetradecanoylphorbol-13-acetate (TPA). Tetradecanoylphorbol Acetate 186-222 insulin like growth factor 1 Homo sapiens 72-77 9813161-4 1998 Treatment with the protein kinase C inhibitors bisindolylmaleimide I and chelerythrine mimicked the augmentation effect of IGF1, whereas PMA blocked enhancement of Mn2+ influx by IGF1. Tetradecanoylphorbol Acetate 137-140 insulin like growth factor 1 Homo sapiens 179-183 9190898-1 1997 While the standard form of CD44 was expressed at high levels in both treated and untreated cells, variant isoforms were strongly upregulated in response to treatment with 12-O-tetradecanoyl phorbol-13-acetate (TPA), insulin-like growth factor-1 (IGF-1) and platelet-derived growth factor (PDGF) as shown by RT-PCR and immunofluorescence. Tetradecanoylphorbol Acetate 210-213 insulin like growth factor 1 Homo sapiens 216-244 9190898-1 1997 While the standard form of CD44 was expressed at high levels in both treated and untreated cells, variant isoforms were strongly upregulated in response to treatment with 12-O-tetradecanoyl phorbol-13-acetate (TPA), insulin-like growth factor-1 (IGF-1) and platelet-derived growth factor (PDGF) as shown by RT-PCR and immunofluorescence. Tetradecanoylphorbol Acetate 210-213 insulin like growth factor 1 Homo sapiens 246-251 9081220-1 1997 Previously, we have shown that IGF-1, the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) and aurintricarboxylic acid (ATA) protected MCF-7 cells against death induced by the protein synthesis inhibitor cycloheximide (CHX). Tetradecanoylphorbol Acetate 94-97 insulin like growth factor 1 Homo sapiens 31-36 8737382-5 1996 Phorbol-12-myristate-13-acetate (PMA) also strongly induced ODC activity in a transient manner, and additively to the effect of IGF-1. Tetradecanoylphorbol Acetate 0-31 insulin like growth factor 1 Homo sapiens 128-133 8737382-5 1996 Phorbol-12-myristate-13-acetate (PMA) also strongly induced ODC activity in a transient manner, and additively to the effect of IGF-1. Tetradecanoylphorbol Acetate 33-36 insulin like growth factor 1 Homo sapiens 128-133 1946468-3 1991 Here we show that the PMA-induced differentiation of SH-SY5Y cells grown in a serum-free medium is strongly potentiated by nanomolar concentrations of IGF-I, as judged by morphology and markers for neuronal differentiation--e.g., neuropeptide tyrosine and growth-associated protein 43. Tetradecanoylphorbol Acetate 22-25 insulin like growth factor 1 Homo sapiens 151-156 7775645-6 1995 PMNLs exposed to IGF-I increased their f-met-leu-phe and phorbol myristate acetate-induced oxidative burst, as evaluated by hydrogen peroxide production, whereas IGF-I did not influence PMNL actin polymerization. Tetradecanoylphorbol Acetate 57-82 insulin like growth factor 1 Homo sapiens 17-22 7734622-0 1995 cAMP and PMA enhance the effects of IGF-I in the proliferation of endometrial adenocarcinoma cell line HEC-1-A by acting at the G1 phase of the cell cycle. Tetradecanoylphorbol Acetate 9-12 insulin like growth factor 1 Homo sapiens 36-41 7734622-6 1995 The interaction of forskolin and PMA with IGF-I was then determined. Tetradecanoylphorbol Acetate 33-36 insulin like growth factor 1 Homo sapiens 42-47 1445344-5 1992 IGF-I and EGF stimulated the transcriptional activity dependent on the phorbol 12-myristate 13-acetate-responsive element (TRE) to the same extent, when measured by the chloramphenicol acetyl transferase activity of a transiently transfected multiple TRE construct. Tetradecanoylphorbol Acetate 71-102 insulin like growth factor 1 Homo sapiens 0-5 2873626-1 1986 In the presence of 12-O-tetradecanoylphorbol-13-acetate (TPA) or the non-TPA-type tumor promoter, palytoxin, recombinant human insulin growth factor-I (IGF-I) and insulin synergistically stimulate prostaglandin production in rat liver cells (the C-9 cell line). Tetradecanoylphorbol Acetate 19-55 insulin like growth factor 1 Homo sapiens 127-150 1652474-4 1991 PMA stimulated phosphorylation of a single major IGF-I receptor phosphoserine peptide which was phosphorylated to a lesser extent after IGF-I. Tetradecanoylphorbol Acetate 0-3 insulin like growth factor 1 Homo sapiens 49-54 2840269-10 1988 When added alone, EGF and TPA increased cAMP production y 2.0-fold and 2.5-fold over controls at 24 h. Again, IGF-I was ineffective. Tetradecanoylphorbol Acetate 26-29 insulin like growth factor 1 Homo sapiens 110-115 3278921-5 1988 Down regulation of PKC activity by treatment with TPA for 48-h blocks the stimulation of S6 kinase by TPA but leaves the activation by EGF, IGF-I and insulin unaffected. Tetradecanoylphorbol Acetate 50-53 insulin like growth factor 1 Homo sapiens 140-145 3009492-5 1986 Treatment of SH-SY5Y cells for 4 d with 12-O-tetradecanoylphorbol-13-acetate (TPA), which resulted in morphological and functional differentiation and growth inhibition, abolished the mitogenic response to both IGF-I and II. Tetradecanoylphorbol Acetate 40-76 insulin like growth factor 1 Homo sapiens 211-223 3009492-5 1986 Treatment of SH-SY5Y cells for 4 d with 12-O-tetradecanoylphorbol-13-acetate (TPA), which resulted in morphological and functional differentiation and growth inhibition, abolished the mitogenic response to both IGF-I and II. Tetradecanoylphorbol Acetate 78-81 insulin like growth factor 1 Homo sapiens 211-223 3009492-7 1986 In contrast, the IGF-I binding in TPA-treated cells was only reduced to approximately 70% of the binding to control cells. Tetradecanoylphorbol Acetate 34-37 insulin like growth factor 1 Homo sapiens 17-22 3009492-8 1986 It is therefore not excluded that the IGF-I receptor could be uncoupled by TPA, with persistent binding capacity for IGF-I. Tetradecanoylphorbol Acetate 75-78 insulin like growth factor 1 Homo sapiens 38-43 2873626-1 1986 In the presence of 12-O-tetradecanoylphorbol-13-acetate (TPA) or the non-TPA-type tumor promoter, palytoxin, recombinant human insulin growth factor-I (IGF-I) and insulin synergistically stimulate prostaglandin production in rat liver cells (the C-9 cell line). Tetradecanoylphorbol Acetate 19-55 insulin like growth factor 1 Homo sapiens 152-157 2873626-3 1986 With both types of stimulations, prostaglandin production or deesterification, the synergistic response of the IGF-I and insulin is greater with palytoxin than with TPA. Tetradecanoylphorbol Acetate 165-168 insulin like growth factor 1 Homo sapiens 111-116 3001088-10 1986 Very similar results, including similar peptide maps, were obtained for the insulin-like growth factor I receptor from cells treated with TPA and insulin-like growth factor I. Tetradecanoylphorbol Acetate 138-141 insulin like growth factor 1 Homo sapiens 76-104